Rallybio Corporation (RLYB)
NASDAQ: RLYB · Real-Time Price · USD
8.21
-0.01 (-0.12%)
At close: Apr 9, 2026, 4:00 PM EDT
8.10
-0.11 (-1.34%)
After-hours: Apr 9, 2026, 4:43 PM EDT

Rallybio Statistics

Total Valuation

Rallybio has a market cap or net worth of $43.43 million. The enterprise value is -$11.13 million.

Market Cap43.43M
Enterprise Value -11.13M

Important Dates

The next estimated earnings date is Thursday, May 7, 2026, before market open.

Earnings Date May 7, 2026
Ex-Dividend Date n/a

Share Statistics

Rallybio has 5.29 million shares outstanding. The number of shares has increased by 3.42% in one year.

Current Share Class 5.29M
Shares Outstanding 5.29M
Shares Change (YoY) +3.42%
Shares Change (QoQ) +0.90%
Owned by Insiders (%) 4.13%
Owned by Institutions (%) 25.84%
Float 2.71M

Valuation Ratios

PE Ratio n/a
Forward PE n/a
PS Ratio 50.62
Forward PS n/a
PB Ratio 0.75
P/TBV Ratio 0.75
P/FCF Ratio n/a
P/OCF Ratio n/a
PEG Ratio n/a
Financial Ratio History

Enterprise Valuation

EV / Earnings n/a
EV / Sales n/a
EV / EBITDA n/a
EV / EBIT n/a
EV / FCF n/a

Financial Position

The company has a current ratio of 14.50, with a Debt / Equity ratio of 0.00.

Current Ratio 14.50
Quick Ratio 12.96
Debt / Equity 0.00
Debt / EBITDA n/a
Debt / FCF n/a
Interest Coverage n/a

Financial Efficiency

Return on equity (ROE) is -15.01% and return on invested capital (ROIC) is -32.69%.

Return on Equity (ROE) -15.01%
Return on Assets (ROA) -30.07%
Return on Invested Capital (ROIC) -32.69%
Return on Capital Employed (ROCE) -54.04%
Weighted Average Cost of Capital (WACC) -2.33%
Revenue Per Employee $61,286
Profits Per Employee -$641,286
Employee Count14
Asset Turnover 0.01
Inventory Turnover n/a

Taxes

Income Tax n/a
Effective Tax Rate n/a

Stock Price Statistics

The stock price has increased by +310.50% in the last 52 weeks. The beta is -1.20, so Rallybio's price volatility has been lower than the market average.

Beta (5Y) -1.20
52-Week Price Change +310.50%
50-Day Moving Average 7.47
200-Day Moving Average 5.39
Relative Strength Index (RSI) 47.87
Average Volume (20 Days) 99,030

Short Selling Information

The latest short interest is 797,895, so 15.08% of the outstanding shares have been sold short.

Short Interest 797,895
Short Previous Month 44,517
Short % of Shares Out 15.08%
Short % of Float 29.46%
Short Ratio (days to cover) 2.54

Income Statement

In the last 12 months, Rallybio had revenue of $858,000 and -$8.98 million in losses. Loss per share was -$1.59.

Revenue858,000
Gross Profit -17.54M
Operating Income -31.36M
Pretax Income -8.98M
Net Income -8.98M
EBITDA -31.27M
EBIT -31.36M
Loss Per Share -$1.59
Full Income Statement

Balance Sheet

The company has $54.74 million in cash and $176,000 in debt, with a net cash position of $54.56 million or $10.31 per share.

Cash & Cash Equivalents 54.74M
Total Debt 176,000
Net Cash 54.56M
Net Cash Per Share $10.31
Equity (Book Value) 57.96M
Book Value Per Share 10.97
Working Capital 57.03M
Full Balance Sheet

Cash Flow

Operating Cash Flow -29.81M
Capital Expenditures n/a
Depreciation & Amortization 92,000
Net Borrowing n/a
Free Cash Flow -29.81M
FCF Per Share -$5.64
Full Cash Flow Statement

Margins

Gross Margin n/a
Operating Margin -3,655.48%
Pretax Margin -1,046.39%
Profit Margin n/a
EBITDA Margin n/a
EBIT Margin n/a
FCF Margin n/a

Dividends & Yields

Rallybio does not appear to pay any dividends at this time.

Dividend Per Share n/a
Dividend Yield n/a
Dividend Growth (YoY) n/a
Years of Dividend Growth n/a
Payout Ratio n/a
Buyback Yield -3.42%
Shareholder Yield -3.42%
Earnings Yield -20.67%
FCF Yield -68.65%

Analyst Forecast

Price Target n/a
Price Target Difference n/a
Analyst Consensus Hold
Analyst Count 2
Revenue Growth Forecast (5Y) 263.41%
EPS Growth Forecast (5Y) n/a
Stock Forecasts

Fair Value

There are several formulas that can be used to estimate the intrinsic value of a stock.

Lynch Fair Value n/a
Lynch Upside n/a
Graham Number n/a
Graham Upside n/a

Stock Splits

The last stock split was on February 6, 2026. It was a reverse split with a ratio of 1:8.

Last Split Date Feb 6, 2026
Split Type Reverse
Split Ratio 1:8

Scores

Rallybio has an Altman Z-Score of -4.02 and a Piotroski F-Score of 3. A Z-score under 3 suggests an increased risk of bankruptcy.

Altman Z-Score -4.02
Piotroski F-Score 3